Search PubMed⌕ Search

PubMed · 8681348

Autonomic receptor--effector coupling during post-natal development.

Abstract

In summary, there are marked age-dependent alterations in the myocardial alpha 1-adrenergic, beta-adrenergic and muscarinic signal transduction cascades. With maturation, an inhibitory alpha 1-adrenergic response appears, which differs from the pre-existing excitatory response both with respect to the specific receptor subtype involved and its G protein coupling. Neurally released NPY appears to play a critical role in regulating the expression of the inhibitory alpha 1-adrenergic response. Likewise, sympathetic innervation appears involved in the loss of an excitatory muscarinic response during development. Again, this response, which is M1 mediated, differs in receptor subtype from that of the M2 inhibitory response characteristic of the adult. Both responses are PT-sensitive, which suggests the involvement of a PT-sensitive G protein in each case, although not necessarily the identical G protein. The role of innervation in developmental regulation of the beta-adrenergic response is unknown. While a distinct beta 1-adrenergic response exists through development, and appears to change predominantly only with respect to magnitude, the beta 2-adrenergic cascade would seem to have somewhat more complex regulation. Not only is the adult normally far less sensitive to beta 2-agonists than the neonate, but the classical beta-adrenergic effect to enhance relaxation along with the increase in force is absent in the adult when the beta 2 (but not beta 1) receptors are activated. It is apparent from the above summary that in the case of all three autonomic receptor systems, the functional signal transduction cascades in the neonate seem designed to favor excitation (chronotropic and/or inotropic) over inhibition. The alpha 1-adrenergic system is exclusively excitatory in the newborn, with an opposing inhibitory cascade only becoming evident after the onset of sympathetic innervation. Similarly, prior to sympathetic innervation the muscarinic system exhibits both excitatory and inhibitory effects, with the excitatory response being lost with development. Finally, while the beta-adrenergic system appears exclusively excitatory at all ages, in the neonate the beta 1- and beta 2-cascades both contribute to the total positive inotropic response to low concentrations of agonist, while in the adult the beta 2-component only contributes at high agonist concentrations. While the reasons for the favoring of excitation cascades in the neonate is not known, it is tempting to speculate on this point. In this respect it is worth noting that in the young, increasing heart rate, rather than stroke volume, is the primary mechanism by which cardiac output is increased [62]. In this situation, excitatory autonomic mechanisms may be advantageous. Also, at the time of birth in the rat (and at other times in different species) there is a period of potential autonomic imbalance when the parasympathetic innervation to the heart is established but the sympathetic innervation is not yet well developed. During this period, having a positive chronotropic component to muscarinic action, and a positive rather than negative alpha 1-adrenergic response, could serve to compensate for any imbalance between the two limbs of the autonomic nervous system. Finally, while the sympathetic innervation of the heart is not fully developed at birth, there can be circulating catecholamines from the adrenal medulla, and these would be primarily epinephrine rather than norepinephrine. Since epinephrine has a much higher affinity than norepinephrine for beta 2-adrenergic receptors, the presence of a strong beta 2-adrenergic cascade in the neonate could be designed to respond to the circulating, rather than neuronal, catecholamines. Lastly, one should not forget that the final physiologic response depends not only on the proximal events of receptor-effector coupling, but on more distal elements that provide the substrate for these autonomic agonists.(ABSTRACT TRUNCATED AT 400 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R B Robinson. 1996. Autonomic receptor--effector coupling during post-natal development.. https://pubmed.ncbi.nlm.nih.gov/8681348/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Impaired maze performance in aged rats is accompanied by increased density of NMDA, 5-HT1A, and alpha-adrenoceptor binding in hippocampus.

Using quantitative receptor autoradiography, we assessed binding site densities and distribution patterns of glutamate, GABA(A), acetylcholine (ACh), and monoamine receptors in the hippocampus of 32-month-old Fischer 344/Brown Norway rats. Prior to autoradiography, the rats were divided into two groups according to their retention performance in a water maze reference memory task, which was assessed 1 week after 8 days of daily maze training. The animals of the inferior group showed less long-term retention of the hidden-platform task but did not differ from superior rats in their navigation performance during place training and cued trials. The decreased retention performance in the group of inferior learners was primarily accompanied by increased alpha(1)-adrenoceptors in all hippocampal subregions under inspection (CA1-CA4 and dentate gyrus), while elevated alpha(2)-adrenoceptor binding was observed in the CA1 region and DG. Furthermore, inferior learners had higher NMDA binding in the CA2 and CA4 and increased 5-HT(1A) binding sites in the CA2, CA3, and CA4 region. No significant differences between inferior and superior learners were evident with regard to AMPA, kainate, GABA(A), muscarinergic M(1), dopamine D(1), and 5-HT(2) binding densities in any hippocampal region analyzed. These results show that increased NMDA, 5-HT(1A), and alpha-adrenoceptor binding in the hippocampus is associated with a decline in spatial memory. The increased receptor binding observed in the group of old rats with inferior maze performance might be the result of neural adaptation triggered by age-related changes in synaptic connectivity and/or synaptic activity.

Adrenergic Agents↗

In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.

We previously clarified that major human drug metabolizing enzymes were expressed in a chimeric urokinase-type plasminogen activator (uPA)+/+/severe combined immunodeficient (SCID) mouse line established recently, in which the liver could be replaced by more than 80% with human hepatocytes. In the present study, we investigated the in vivo drug metabolism of a CYP2D6 substrate, debrisoquin (DB), in chimeric mice with high (High) or low (Low) human albumin (hAlb) concentrations and in control uPA-/-/SCID mice. The hAlb in the mouse blood is one of the indices of humanized liver because the chimeric mice produce hAlb. After oral administration of DB at 2.0 mg/kg, the AUC0-8 value of a major CYP2D6 metabolite of DB, 4'-hydroxydebrisoquin (4-OH DB), in High was 3.6-fold higher than those of Low and uPA-/-/SCID mice. By pre-treatment with a typical CYP2D6 inhibitor, quinidine, the AUC0-8 value of 4-OH DB in High was decreased although such values in Low and uPA-/-/SCID mice did not change. The in vitro kinetic analyses and the Ki values of quinidine on the DB 4'-hydroxylase activity in liver microsomes also supported the humanization of the chimeric mice. In conclusion, the chimeric mice exhibited a humanized profile of drug metabolism and the inhibition of P450.

Adrenergic Agents↗

Adrenergic and cholinergic compounds.

Adrenergic and cholinergic signalling contributes significantly to the endogenous antinociceptive system. Exogenous alpha 2 adrenergic agonists have a well-established analgesic profile; however, recent investigations suggest that this class of agents is underused, and herein we highlight the potential for both current application and future development of these agents. Nicotinic and muscarinic cholinergic ligands represent a novel class of agents with much promise for the management of problematic pain. In this chapter we review advances in both preclinical and clinical arenas and highlight potential avenues for further research.

Adrenergic Agents↗